PerCP/Cyanine5.5 Anti-Human CD38 Antibody[HIT2]

The PERCP/CYANINE5.5 Anti-Human CD38 Antibody [HIT2] is a highly specific and reliable tool for the detection and analysis of CD38 expression in human samples. This monoclonal antibody is conjugated with the PERCP/CYANINE5.5 fluorochrome, which provides excellent brightness and stability, ensuring accurate and consistent results.

CD38 is a transmembrane glycoprotein that plays a crucial role in various physiological and pathological processes, including cell adhesion, signal transduction, and immune response modulation. Its expression has been associated with several diseases, such as multiple myeloma, chronic lymphocytic leukemia, and autoimmune disorders. Therefore, the ability to accurately measure CD38 expression is of great importance in both research and clinical settings.

The PERCP/CYANINE5.5 Anti-Human CD38 Antibody [HIT2] offers exceptional sensitivity and specificity, allowing for precise identification and quantification of CD38-positive cells. Its high affinity for CD38 ensures minimal background noise and reliable detection, even at low expression levels. Additionally, the PERCP/CYANINE5.5 fluorochrome provides superior brightness, enabling clear discrimination of positive and negative populations.

This antibody is suitable for various applications, including flow cytometry, immunohistochemistry, and immunofluorescence. Its compatibility with multiple techniques allows for comprehensive analysis of CD38 expression in different sample types, such as peripheral blood, bone marrow, and tissue sections. Furthermore, the PERCP/CYANINE5.5 conjugation ensures long-term stability and consistent performance, making it an ideal choice for long-term studies and large-scale experiments.

In summary, the PERCP/CYANINE5.5 Anti-Human CD38 Antibody [HIT2] is a highly reliable and specific tool for the detection and analysis of CD38 expression. Its exceptional sensitivity, brightness, and stability make it an invaluable asset for researchers and clinicians studying CD38-related diseases and exploring potential therapeutic targets.